What might a Trump administration mean for the Biosecure Act?

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.

Sage’s string of research failures continues

Negative results from a Huntington’s trial add to a difficult year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.

Leveraging NGS to move precision oncology forward, from CDx to commercialization

Chasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is designing drugs to target glyco-immune checkpoints.

Flagship, Pfizer alliance yields two more startup deals

Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.